Akatinol Memantine, 10 mg, 90 pcs.

Coated tablets

1 tab.:

memantine hydrochloride 10 mg

Excipients:

lactose;

MCC;

silicon dioxide colloidal;

talc;

magnesium stearate shell:

 methacrylic acid copolymer;

sodium lauryl sulfate;

polysorbate 80;

triacetin;

simethicone emulsion;

talc 

Akatinol Memantine is a central muscle relaxant.

Being a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptors, it has a modulating effect on the glutamatergic system.

Regulates ion transport, blocks calcium channels, normalizes membrane potential, improves the transmission of nerve impulses, improves cognitive processes, memory and learning ability, and increases daily activity.

• Alzheimer's type dementia, vascular dementia, mixed dementia of all degrees of severity.
• Decreased memory, ability to concentrate, and learning ability.
• Cerebral and spinal spastic syndrome, including due to traumatic brain injury, multiple sclerosis, stroke.

Contraindicated in pregnancy.

At the time of treatment should stop breastfeeding.

• individual hypersensitivity to the drug;
• severe renal impairment;
• pregnancy;
• breast-feeding;
• children under 18 years old (due to insufficient data).

Carefully:

• thyrotoxicosis;
• epilepsy;
• convulsions (including history);
• myocardial infarction;
• heart failure.

Adverse reactions are classified by clinical manifestations (in accordance with the defeat of certain organ systems) and by the frequency of occurrence: very often - ≥1 / 10; often - ≥1 / 100–

On the part of the body as a whole - general adverse reactions

Often

Headache

Seldom

Fatigability

Infections

Seldom

Fungal infections

Mental disorders

Often

Drowsiness

Seldom

Confusion

Seldom

Hallucinations

Frequency not set

Psychotic reactions

Disorders of the cardiovascular system

Rarely hypertension

Rarely Venous Thrombosis / Thromboembolism

Gastrointestinal Disorders

Often constipation

Rarely Nausea, Vomiting

Frequency not set

Pancreatitis

Disorders from the central and peripheral nervous system

Often Dizzy

Rarely Gait Disorder

Very rare cramps

1 Hallucinations have been observed mainly in patients with Alzheimer's disease in severe dementia.

2 There are separate reports of the occurrence of these adverse reactions when using the drug in clinical practice (data obtained after the drug was commercially available).

With simultaneous use with L-dopa drugs, dopamine agonists, anticholinergics, the effect of the latter may be enhanced.

With simultaneous use with barbiturates, antipsychotics, the effect of the latter may decrease.

When used together, it can change (strengthen or reduce) the effect of dantrolene or baclofen, so the doses of drugs should be selected individually.

Concurrent administration with amantadine, ketamine, and dexamethorphan should be avoided.

Possible increase in plasma levels of cimetidine, procainamide, quinidine, kinin and nicotine while taking with memantine.

It is possible to reduce the level of hydrochlorothiazide while taking it with memantine.

Akatinol Memantine is taken orally during meals. The dosage regimen is set individually. It is recommended to start treatment with the appointment of minimally effective doses.

Adults with dementia during the 1st week of therapy - at a dose of 5 mg / day, 2nd week - at a dose of 10 mg / day, 3rd week - at a dose of 15-20 mg / day. If necessary, a further weekly increase in dose of 10 mg is possible until a daily dose of 30 mg is reached.

The optimal dose is achieved gradually, with increasing doses every week.

Symptoms: increased severity of side effects.

Treatment: gastric lavage, intake of activated carbon, symptomatic therapy.

In patients with moderate to severe dementia, Alzheimer's disease usually impairs the ability to drive vehicles and control complex mechanisms.

In addition, memantine can cause a change in the reaction rate, so patients receiving treatment on an outpatient basis should be especially careful when driving vehicles or operating machinery.

Coated tablets.